Nuance Story
2022
2021
2020
2019
2018
2015
2014
2022
Licensed in First-in-Class MVA-BN-RSV Vaccine from Bavarian Nordic. IND approval for MVA-BN RSV vaccine China phase 3 clinical trial
Licensed in allergy / virus prevention nasal spray Bentrio™ from Altamira. Launched Bentrio™ in Hong Kong as Asia expansion strategy
IND approval for Ensifentrine China phase 1 / 3 clinical trials

2021
Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma
Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma
Acquired Sino Health (Yinglian) with access to 3 commercial products in emergency care and a GSP license

2020
Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum
Raised US$ 181 million Series D equity funding

2019
Acquired NIFEREX Iron Polysaccharide Complex Capsules

2018
Established exclusive partnership with Aerogen Pharma on nebulizer device
Accumulatively raised US$ 80 million equity funding

2015
Established Commercial Platform for footprint in China

2014
Mr. Mark Lotter founded Nuance Pharma in Shanghai
